Business & Finance
Sun Pharma reports Q1FY19 results
15 August 2018 -

Sun Pharmaceutical Industries Ltd an India-based pharmaceutical company, yesterday reported its financial results for the first quarter 2019, ending 30 June 2018.

The company reported sales/income from operations for its first quarter at INR71,390,000,000 (USD1,014,594,680), a growth of 16% over the same quarter last year. EBITDA was INR15,210,000,000 (USD216,164,520), resulting in an EBITDA margin of 21.3%.

Net profit for Q1 2019 was INR9,830,000,000 (USD139,703,960), up by 87% over the same period last year, when profit was adversely affected by legal settlements.

Dilip Shanghvi, managing director of the company, said, 'For Q1, we have recorded good growth in all the major markets. We are gradually crossing key milestones in our specialty initiatives with the recent commercialisation of Yonsa in the US and targeted launch of Ilumya and Cequa in the coming quarters. We are also awaiting approvals from US FDA for two specialty products, Xelpros and Elepsia, filed from Halol. With all these specialty launches lined-up, a substantial portion of our current specialty pipeline will be on market. We are creating a deep pipeline of specialty products, however, during the year these launches will result in significant upfront investments. We continue to evaluate opportunities in the specialty segment to further enhance this business.'

Login
Username:

Password: